Clinical beta notice

Disclaimer: These workbenches are the work of a single person, Dr. Ali Al-Ibrahim, they are all in beta and might have errors. Please report bugs, errors and improvements to Alioud16@gmail.com.

Intended use, evidence & limitations

Phenotype-led prenatal genomic testing; conditional inheritance / carrier-risk teaching; laboratory-led variant, CNV and ROH review; family history, counselling choices and result / reanalysis planning. No automated classification or consent.

Professional workbench in beta. Review sources, model scope and units before interpreting outputs. Software verification does not establish clinical validation.

Methods & evidence standards ↗
FETAL GENOMICS · EVIDENCE WITHOUT OVERPROMISE

Genetic Counseling &
Fetal Genomics Workbench

A clearer question.
A more informed next step.

Phenotype · Family · GenomeClinical approval pending
Fictional teaching cases — replace current entries only after confirmation
CLINICAL ENTRY

A clear question. A traceable plan.

Tab moves forward; Shift+Tab returns. Enter advances text / number fields. Native select and Space keys are preserved. Ctrl / ⌘ + Enter reviews.

1 · Clinical question0 recorded

Start with the question and the patient’s goals. No normal fetus, healthy parent, completed consent, test choice or gestation is assumed.

Urgent clinical care must not wait for a genomic result.
2 · Fetal phenotype0 recorded

Record observed, absent and unassessed findings separately. “Isolated” requires a detailed survey; no genetic-yield score or syndrome ranking is calculated.

Record source / observed GA; identifiers are not automatically validated or matched to syndromes.
3 · Existing tests0 recorded

Enter the actual scope and specimen of prior testing. A normal rapid result, karyotype, CMA or exome answers different questions. Nothing is inferred from a blank field.

4 · Sampling & laboratory plan0 recorded

Plan the specimen and the analysis separately. This is not procedural clearance, an order or signed consent. No automatic procedure-loss estimate is assigned to the individual.

5 · Molecular transmission0 recorded

This is a conditional teaching model, not a diagnosis / severity predictor. Use verified genotypes for the same disease mechanism; “unaffected” is not a genotype.

6 · AR carrier & residual risk0 recorded

Single-condition autosomal-recessive model only. Do not use a VUS as a confirmed disease allele, assume a whole-panel residual risk or infer a Mendelian recurrence percentage from family history alone.

7 · Screening risk communication0 recorded

A transparent arithmetic aid using user-supplied assumptions, not a source of disease prevalence or test performance. No-call / mosaic / unvalidated contexts do not produce ordinary Bayesian PPV / NPV.

Do not multiply correlated tests or use a laboratory’s post-test PPV again as the prior.
8 · Sequence-variant review0 recorded

Capture the signed laboratory interpretation and its evidence. No ACMG checkbox sum, autonomous classification or inferred fetal diagnosis is provided.

Text is recorded, not normalized or validated against a sequence.
Capture supporting and opposing data. PM2 rarity is not a generic moderate score; avoid duplicate evidence.
9 · CNV, ROH & chromosome review0 recorded

Coordinates are 1-based, closed base pairs from the original report. Build must be explicit; no automatic liftover, coordinate sorting / clipping, gene overlap, severity score or classification.

10 · Counselling & choices0 recorded

These are user-recorded discussion items, not proof of understanding, signed consent or permission to send data. Separate procedure, fetal testing and each parent’s own sequencing choices.

No default secondary-finding gene list is applied to fetal testing; document what this laboratory offers and to whom.
11 · Results & recontact0 recorded

A testing plan is incomplete without a named owner, result-return date, interpretation review and a plan for negative / uncertain results or an evolving phenotype.

QUESTION → EVIDENCE → SHARED DECISION → RESULT RETURN

Define the question before choosing a test

An excellent genetics consultation makes the next question clearer—not the uncertainty invisible.

THE QUESTIONNot selectedGA Not recorded
CLINICAL PHENOTYPENot establishedNo finding selected ≠ normal fetus
MOLECULAR CONCLUSIONLaboratory-ledNo automated variant / syndrome classification
4 unresolved assessment items
  • Original test reports / specimen / scope have not been verified.
  • Actual phenotype / imaging source and completeness have not been verified.
  • Choose the main clinical question.
  • Name the result-return owner and due review / contact time.

No age-based default prior, syndrome score, genetic-yield grade, presumed parental genotype, automatic VUS classification or completed consent is supplied.

No valid current case report available.

Case entries stay in page memory. No new stored-case reads, persistence, external variant lookup or transmission is introduced. Reload / Reset all clears the in-memory case; it cannot erase records already copied, printed or downloaded. A family map, report draft or accept choice is not clinical certification or signed consent.

Clear this input section?

Visible and hidden fields in this section return to blank / unknown. Other sections remain; current model / source / handover acknowledgements are invalidated.

Choose the question before the test

100%
Original testing pathway: verify imaging and prior reports; distinguish a known familial diagnosis, major or recurrent anomaly and an apparently isolated soft marker; coordinate the specimen and analysis separately, then name the result-return owner. No automatic diagnostic yield or test order.

Match the question, mechanism and phenotype to the test. CMA / selected sequencing, familial testing and isolated-marker guidance are different paths—not a single escalating checklist.

Original vector teaching artwork · Not a complete protocol · Clinical / illustration approval pending.

Workbench Reference & About

Version: 2.0 local review
Guideline version: ACOG January 2026 / SMFM; ISPD; ACMG / AMP / ClinGen; RCOG; assay-specific local laboratory policy
Last reviewed date: 20 October 2026
Formula source: Conditional Mendelian genotype transmission; sourced-user-assumption Bayes / single-condition AR residual arithmetic; exact GRCh37 / GRCh38 interval bounds
Coefficient source: No default prevalence / test performance, cousin adjustment, syndrome-yield score, autonomous variant classifier or universal de novo / mitochondrial disease risk
Validation notes: Local software / browser checks; independent genetics, MFM, cytogenetics / molecular laboratory and consent / data-policy approval required
Known limitations: Not diagnosis, prognosis, procedural clearance, a test order, signed consent or live gene / assay guidance. Molecular transmission is not penetrance. Clinical interface is English; local-language and institutional validation remain required.
What changed in this version: Controlled React rebuild; phenotype-led testing; corrected genotype / carrier models; laboratory-led variant / CNV / ROH review; honest family map and consent; five current drafts; keyboard / reset safeguards; four original algorithms.
© 2026 Dr. Ali Hussein Al Ibrahim. All rights reserved.